HIF-2 directly activates CD82
gene expression in endothelial cells.
If this first IHC panel is inconclusive, additional markers, such as CD82, claudin 7, and claudin 8, can be used.
Differential Diagnosis of Low-Grade Renal Cell Tumor With Clear Cell/Granular Cell Features3 Antibodies ChRCC Oncocytoma CRCC CK7 Diffusely + -/focally + - Ber-EP4 Diffusely + -/focally + ND S100A1 - + +/- CD15 - +/- - CD82 + - -/+ Claudin 7 + - ND Claudin 8 M+ C+ ND CD117 + + - RCCma - - + CAIX - - + KIM-1 - - + Vim - - + Abbreviations: C, cytoplasmic; ChRCC, chromophobe renal cell carcinoma; CRCC, clear cell renal cell carcinoma; M, membranous.
The CD73 can be upgraded to the CD82
or the CD192 by the factory at any time.
2/8H5) from LifeSpan BioSciences (Seattle, WA, USA); Annexin V (AF399), CD4 (34930), CD8a (37006), CD19 (4G7-2E3), CD37 (424925), CD45 (2D1), CD80 (37711), CD82 (423524), CD83 (HB15e), MIC A/B (159207), TNF RI, and TNF RII from R&D Systems (Minneapolis, MN, USA); TLR3 (3.
CD82 was detected at high levels on sEVs from monocytes and PBMCs and at very low levels on sEVs from B cells and T cells but was absent on sEVs from NK cells.
Immunological markers Functional Regulatory Adhesion Lineage-specific and others HLA-DR CTLA-4 CD11a CD3 HLA-ABC PD-L1 ICAM-1 CD4 CD28 CD8 CD80 CD14 CD49d CD16 TLR3 CD19 Fas-L CD37 MIC A/B CD41 TNF RI CD42a TNF RII CD45 CD56 CD83 Vesicle-related markers Functional Tetraspanins Others HLA-DR CD9 TSG101 HLA-ABC CD63 Alix CD28 CD81 Flotillin-1 CD80 CD82 Annexin V CD49d TLR3 Fas-L MIC A/B TNF RI TNF RII HLA: human leukocyte antigen; TLR: Toll-like receptor; TNF: tumor necrosis factor: RI: receptor I, RII: receptor II; MIC A-B: major 1; TSG101: tumor susceptibility gene 101.
Some studies have shown the value of S100A1 and CD82
in distinguishing chromophobe RCC from oncocytoma, (64,65) but those findings need to be further verified.
74,89,90) Unlike the type II form of EATL, the extranodal NK/T-cell lymphomas generally are CD82
and also are negative for PF1.
Exceptions do occur, and counting the CD82
IELs alone may not be sufficient for a differential diagnosis between refractory sprue and EATL.
CD82 (26,32) is known to be a metastasis suppressor gene, which can block one or more steps along the downstream metastatic cascade, without affecting primary tumor growth.
Therefore, a panel, including S100A1 and CD82, may help to differentiate chromophobe RCC from oncocytoma.